Metacrine, Inc.: Nasdaq/NYSE listing notice — Metacrine receives Nasdaq delisting notice; stock to move to OTCQX Feb 9

Metacrine, Inc.

Nasdaq notified Metacrine on Jan 31, 2023 that its common stock will be delisted for failing to meet minimum bid price requirement.
Company will not appeal the delisting determination.
Trading suspended at open on Feb 9, 2023; stock expected to trade on OTCQX under symbol MTCR.
Previous compliance deadline was Jan 30, 2023; company failed to regain compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Metacrine, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 31, 2023, the Company received written notice (the “Delisting Notice”) from Nasdaq notifying the Company that, as a result of its failure to regain compliance with the Minimum Bid Price Requirement for continued listing on the Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2), Nasdaq has determined that the Company’s common stock will be delisted from the Nasdaq Capital Market. The Delisting Notice indicated that the Company may appeal Nasdaq’s determination pursuant to procedures set forth in Nasdaq Listing Rule 5800 Series. The Company will not appeal this determin

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-021568

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.